CL2022003689A1 - Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4) - Google Patents
Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4)Info
- Publication number
- CL2022003689A1 CL2022003689A1 CL2022003689A CL2022003689A CL2022003689A1 CL 2022003689 A1 CL2022003689 A1 CL 2022003689A1 CL 2022003689 A CL2022003689 A CL 2022003689A CL 2022003689 A CL2022003689 A CL 2022003689A CL 2022003689 A1 CL2022003689 A1 CL 2022003689A1
- Authority
- CL
- Chile
- Prior art keywords
- adjuvant
- tlr4
- toll
- receptor
- agonist activity
- Prior art date
Links
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 title 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000012646 vaccine adjuvant Substances 0.000 abstract 2
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/248—Colchicine radicals, e.g. colchicosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020107194 | 2020-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003689A1 true CL2022003689A1 (es) | 2023-07-28 |
Family
ID=79281148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003689A CL2022003689A1 (es) | 2020-06-22 | 2022-12-21 | Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230287027A1 (https=) |
| EP (1) | EP4169527A4 (https=) |
| JP (1) | JPWO2021261444A1 (https=) |
| KR (1) | KR20230026438A (https=) |
| CN (1) | CN116056721A (https=) |
| AU (1) | AU2021295796A1 (https=) |
| BR (1) | BR112022025969A2 (https=) |
| CA (1) | CA3187828A1 (https=) |
| CL (1) | CL2022003689A1 (https=) |
| IL (1) | IL299253A (https=) |
| MX (1) | MX2022016181A (https=) |
| PE (1) | PE20230463A1 (https=) |
| PH (1) | PH12022553464A1 (https=) |
| SA (1) | SA522441781B1 (https=) |
| WO (1) | WO2021261444A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026018889A1 (ja) * | 2024-07-19 | 2026-01-22 | 住友ファーマ株式会社 | ワクチンアジュバントを含むリポソーム製剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| ATE518874T1 (de) | 1999-11-15 | 2011-08-15 | Oncothyreon Inc | Synthetische lipid-a analogen und verwendungen davon |
| CN101863930A (zh) | 2003-01-06 | 2010-10-20 | 科里克萨有限公司 | 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途 |
| US7807720B2 (en) | 2007-02-01 | 2010-10-05 | Panthera Biopharma, Llc | Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning |
| CN105188710A (zh) * | 2013-03-15 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途 |
| EP3242883A4 (en) * | 2015-01-06 | 2018-10-17 | ImmunoVaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
| JP7362667B2 (ja) * | 2018-02-12 | 2023-10-17 | イニミューン・コーポレーション | Toll様受容体リガンド |
-
2021
- 2021-06-21 IL IL299253A patent/IL299253A/en unknown
- 2021-06-21 PH PH1/2022/553464A patent/PH12022553464A1/en unknown
- 2021-06-21 US US18/011,586 patent/US20230287027A1/en active Pending
- 2021-06-21 MX MX2022016181A patent/MX2022016181A/es unknown
- 2021-06-21 CA CA3187828A patent/CA3187828A1/en active Pending
- 2021-06-21 BR BR112022025969A patent/BR112022025969A2/pt unknown
- 2021-06-21 EP EP21829834.7A patent/EP4169527A4/en not_active Withdrawn
- 2021-06-21 KR KR1020237001883A patent/KR20230026438A/ko active Pending
- 2021-06-21 PE PE2022002961A patent/PE20230463A1/es unknown
- 2021-06-21 JP JP2022531976A patent/JPWO2021261444A1/ja not_active Withdrawn
- 2021-06-21 WO PCT/JP2021/023402 patent/WO2021261444A1/ja not_active Ceased
- 2021-06-21 CN CN202180051288.3A patent/CN116056721A/zh active Pending
- 2021-06-21 AU AU2021295796A patent/AU2021295796A1/en not_active Abandoned
-
2022
- 2022-12-18 SA SA522441781A patent/SA522441781B1/ar unknown
- 2022-12-21 CL CL2022003689A patent/CL2022003689A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116056721A (zh) | 2023-05-02 |
| BR112022025969A2 (pt) | 2023-01-17 |
| PE20230463A1 (es) | 2023-03-14 |
| EP4169527A4 (en) | 2025-03-05 |
| MX2022016181A (es) | 2023-02-13 |
| SA522441781B1 (ar) | 2024-08-11 |
| CA3187828A1 (en) | 2021-12-30 |
| US20230287027A1 (en) | 2023-09-14 |
| JPWO2021261444A1 (https=) | 2021-12-30 |
| IL299253A (en) | 2023-02-01 |
| WO2021261444A1 (ja) | 2021-12-30 |
| EP4169527A1 (en) | 2023-04-26 |
| PH12022553464A1 (en) | 2024-03-04 |
| KR20230026438A (ko) | 2023-02-24 |
| AU2021295796A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386981B (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). | |
| MX2021011728A (es) | Agonista beta adrenergico y metodos de uso de este. | |
| CL2021001430A1 (es) | Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422) | |
| PE20211290A1 (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson | |
| MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| ECSP10010518A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 | |
| MX2017014621A (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma. | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| MX393782B (es) | Formulaciones a largo plazo | |
| MX2025004075A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos | |
| CL2021003272A1 (es) | Composición farmacéutica parenteral del agonista dual glp1/2 | |
| ECSP21088111A (es) | Analogos de 3(5metil1,3tiazol2il)n{(1r)1[2(trifluormetil)pirimidin5il]etil}benzamida | |
| MX2023009282A (es) | Compuesto profarmaco, metodo de preparacion del mismo y uso del mismo. | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| BR112023000220A2 (pt) | Formulações de longa ação | |
| HN2003000162A (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen. | |
| DOP2022000203A (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52 | |
| CL2022003689A1 (es) | Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4) | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| AR050914A1 (es) | Agonista receptor de vasopresina peptidico | |
| MX2021012201A (es) | Adyuvante soluble en agua. | |
| MX2024001396A (es) | Conjugados anticuerpo-fármaco y métodos de uso de estos. | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| DOP2022000075A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 |